Medpace Holdings’ Earnings Call Signals Growth Amid Volatility

Medpace Holdings Inc ((MEDP)) has held its Q4 earnings call. Read on for the main highlights of the call.

Medpace Holdings Inc. struck an upbeat tone on its latest earnings call, underscoring powerful revenue and EBITDA growth, strong cash generation, and aggressive share buybacks, even as it acknowledged rising cancellations and some margin pressure. Management framed the operational headwinds as transitory, stressing that a healthy backlog and disciplined execution should support continued expansion into 2026.

Revenue Soars in Q4 and Full Year 2025

Medpace delivered Q4 2025 revenue of $708.5 million, a 32% increase from the prior year and a clear sign of strong demand for its clinical research services. Full year 2025 revenue reached $2.53 billion, up 20% from 2024, confirming that the business is scaling rapidly across its customer base.

Healthy Net New Business and Expanding Backlog

Net new business awards in Q4 climbed 39.1% year over year to $736.6 million, translating to a net book‑to‑bill ratio of 1.04 despite elevated cancellations. The company closed the year with an approximately $3.0 billion backlog, up 4.3% from 2024, with about $1.9 billion expected to convert to revenue within 12 months and a Q4 conversion rate of 23.6%.

Profit Growth in Absolute Terms Despite Margin Pressure

Profitability advanced solidly, with Q4 EBITDA rising 20% to $160.2 million and full year EBITDA up 16.1% to $557.7 million, even though percentage margins slipped. Net income followed a similar pattern, with Q4 profit of $135.1 million up 15.5% and full year net income of $451.1 million increasing 11.6% from 2024 levels.

EPS Acceleration and Aggressive Share Repurchases

Earnings per share moved ahead faster than net income as Medpace continued to shrink its share count through buybacks. Diluted EPS climbed to $4.67 in Q4 from $3.67 a year earlier and to $15.28 for 2025 from $12.63 in 2024, while the company repurchased 2.96 million shares for $912.9 million and still has $821.7 million remaining under its authorization.

Strong Cash Generation and Favorable Working Capital

The company’s cash engine remained a highlight, with $192.7 million in cash generated from operating activities in the fourth quarter alone and a year‑end cash balance of $497 million. Net days sales outstanding were a striking negative 58.7 days, signaling highly favorable working capital dynamics and rapid cash collection relative to billings.

Operational Discipline in Headcount and Productivity

Management outlined plans for mid‑ to high‑single‑digit headcount growth in 2026, faster than 2025 hiring but still trailing expected revenue gains to protect margins. The strategy leans on improved employee retention and productivity enhancements to deliver more work per person, positioning Medpace to absorb growth without a proportional increase in operating costs.

Spike in Cancellations Weighs on Bookings Quality

Q4 saw the highest level of backlog cancellations in both dollar and percentage terms in over a year, which held the net book‑to‑bill ratio to 1.04 and reduced the quality of reported awards. Management said cancellations were broad‑based across clients rather than driven by a single sponsor, suggesting a sector‑wide, though possibly temporary, wobble in certain programs.

EBITDA Margin Compression in 2025

Despite higher profits in dollars, Medpace’s EBITDA margin compressed to 22.6% in Q4 from 24.9% a year earlier and to 22.0% for the full year from 22.8% in 2024. The company attributed the decline largely to a shift in mix toward higher reimbursable activity, which raises reported revenue but produces lower margin percentages on that incremental volume.

Elevated Reimbursable and Pass‑Through Cost Exposure

Pass‑through and reimbursable costs, many tied to complex metabolic trials, were elevated and are expected to remain high into 2026, shaping both the revenue profile and margin optics. Management guided that reimbursables should represent roughly 41%–42% of revenue next year and will start 2026 at a higher level than year‑end 2025, which may temper reported top‑line growth and keep some margin pressure in place.

Metabolic Trial Cancellations Add Segment Volatility

The spike in Q4 cancellations was skewed toward metabolic programs, including obesity, diabetes, and NASH, where some studies were cut short after compounds underperformed. This concentration introduces short‑term volatility and highlights risk around one of Medpace’s more active therapeutic areas, even though management portrayed the issue as program‑specific rather than structural.

Net Income Trailing EBITDA Growth

Net income growth lagged EBITDA expansion, reflecting headwinds below the operating line rather than core business weakness. The company cited lower interest income compared with the prior year and a slightly higher effective tax rate as the main reasons why net income rose 15.5% in Q4 and 11.6% for the full year, trailing the 20% and 16.1% increases in EBITDA.

Assumptions and Risks Embedded in Outlook

The 2026 framework assumes a normalization of cancellation activity and excludes any future share repurchases, which could otherwise lift EPS. Management also flagged potential risk from a persistently high reimbursable mix early in the year and uncertainty over how quickly AI‑enabled productivity tools will translate into tangible margin benefits, leaving some execution risk around the guidance ranges.

2026 Guidance Points to Continued, If Moderating, Growth

For 2026, Medpace forecast revenue between $2.755 billion and $2.855 billion, implying 8.9% to 12.8% growth over 2025, and projected EBITDA of $605 million to $635 million, up 8.5% to 13.9%. The company expects net income of $487 million to $511 million and diluted EPS of $16.68 to $17.50, based on roughly 29.2 million diluted shares and an effective tax rate of 18.5%–19.5%, with about $1.9 billion of backlog slated to convert into revenue.

Medpace’s earnings call painted the picture of a company balancing clear growth momentum with manageable, largely cyclical headwinds tied to cancellations and mix. For investors, the combination of double‑digit historical expansion, solid 2026 guidance, strong cash generation, and ongoing shareholder returns positions the stock as a growth story with near‑term volatility but intact long‑term fundamentals.